Literature DB >> 35125494

Local versus systemic treatment intensification: what is the optimal strategy for localized prostate cancer?

Zachary S Zumsteg1,2.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35125494     DOI： 10.1038/s41391-022-00505-w

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN： 1365-7852            Impact factor:   5.554


× No keyword cloud information.
  6 in total

1.  Radiotherapy and short-term androgen deprivation for localized prostate cancer.

Authors:  Christopher U Jones; Daniel Hunt; David G McGowan; Mahul B Amin; Michael P Chetner; Deborah W Bruner; Mark H Leibenhaut; Siraj M Husain; Marvin Rotman; Luis Souhami; Howard M Sandler; William U Shipley
Journal:  N Engl J Med       Date:  2011-07-14       Impact factor: 91.245

2.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

Authors:  Miljenko V Pilepich; Kathryn Winter; Colleen A Lawton; Robert E Krisch; Harvey B Wolkov; Benjamin Movsas; Eugen B Hug; Sucha O Asbell; David Grignon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

3.  Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities.

Authors:  Nicholas G Zaorsky; Scott W Keith; Talha Shaikh; Paul L Nguyen; Eric M Horwitz; Adam P Dicker; Robert B Den
Journal:  Am J Clin Oncol       Date:  2018-04       Impact factor: 2.339

4.  Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.

Authors:  Charles N Catton; Himu Lukka; Chu-Shu Gu; Jarad M Martin; Stéphane Supiot; Peter W M Chung; Glenn S Bauman; Jean-Paul Bahary; Shahida Ahmed; Patrick Cheung; Keen Hun Tai; Jackson S Wu; Matthew B Parliament; Theodoros Tsakiridis; Tom B Corbett; Colin Tang; Ian S Dayes; Padraig Warde; Tim K Craig; Jim A Julian; Mark N Levine
Journal:  J Clin Oncol       Date:  2017-03-15       Impact factor: 44.544

5.  External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

Authors:  Michel Bolla; Geertjan Van Tienhoven; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Ignace Billiet; José Lopez Torecilla; Raphael Pfeffer; Carmel Lino Cutajar; Theodore Van der Kwast; Laurence Collette
Journal:  Lancet Oncol       Date:  2010-10-07       Impact factor: 41.316

6.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Andrew A Renshaw; Marian Loffredo; Philip W Kantoff
Journal:  JAMA       Date:  2008-01-23       Impact factor: 56.272
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.